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Abstract
Background: Isolated orofacial clefts are among the most common congenital birth defects. Although the
underlying biological mechanisms remain largely unknown, clefts are thought to be complex disorders influenced
by genetic, environmental, and potentially epigenetic factors.
Methods: In blood samples from 2- to 3-day-old infants (n = 747) collected in a nationwide population-based study
of orofacial clefts in Norway, we measured DNA methylation profiles for more than 450,000 CpGs and then conducted
epigenome-wide association analyses (EWAS). We tested methylation profile difference at each CpG between controls
(n = 436) and each of the cleft subtypes (92 cleft lip only, CLO; 84 cleft palate only, CPO; 132 cleft lip and palate, CLP).
We also compared controls to various combinations of case groups and compared case subtypes to each other. Finally,
using the EWAS results, we searched for larger differentially methylated regions (DMRs) associated with orofacial clefts.
Results: In EWAS comparing controls to individual cleft subtypes, we found no significant associations at a Bonferroni
P value threshold of 10−7. After pooling case groups, we found two significantly differentially methylated CpGs:
cg09696939 near gene BICC1 is associated with CLO+CLP (P = 9.58 × 10−8); cg26985354 in gene CLASRP is associated
with CPO+CLP (P = 7.38 × 10−8). In DMR analysis, we identified a total of 56 significant regions when comparing
controls to individual cleft subtypes (10 for CLO, 6 for CPO, 41 for CLP). Only one DMR is shared among the three cleft
groups. In combined case group analysis, we found 26 DMRs for CLP+CLO, 31 for CLP+CPO, and 37 when all subtypes
are combined. Finally, in case-case comparisons of subtypes, we identified 10 DMRs when comparing CLP to CPO, 9 in
CLP compared to CLO, and 13 in CLP compared to CPO.
Conclusions: We identified two individual CpGs and multiple DMRs that differ between controls and cleft case
subtypes. Although we find some evidence for the possible role of DNA methylation in etiology of orofacial clefts, our
study does not support previous reports of widespread differences in blood DNA methylation between babies with
and without facial clefts.
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Background
Orofacial clefts are among the most common con-
genital birth defects. Approximately 250,000 babies
are born with these defects each year worldwide
(http://cleft.org.uk/), and the prevalence varies by eth-
nicity, sex [1], and socioeconomic status [2]. Orofacial
clefts, which include three distinct subgroups, cleft lip
only (CLO), cleft lip and palate (CLP), and cleft pal-
ate only (CPO), result from fusion failures in weeks 5
(fusion of lip) and 9 (fusion of palate) from date of
conception. An orofacial cleft that is left unrepaired
can have a substantial adverse impact on the health,
quality of life, and psychosocial well-being of the
child. Full repair of clefts entails surgery, dental treat-
ment, and speech therapy, imposing financial and
emotional burden on families [3].
Approximately 70% of orofacial clefts are non-syn-
dromic [1], and the underlying causes of these isolated
cases are complex and remain largely unknown. Al-
though familial recurrence risk estimates and segrega-
tion analysis [4–6] suggest there is strong evidence for a
genetic component, environmental factors like smoking,
vitamin intake, and alcohol intake may also play an im-
portant role [7–9]. To date, whole genome linkage and
SNPs identified through genome-wide association stud-
ies can explain only a small percentage of the disease
variation [1, 10]. Several recent studies [8, 11–13] sup-
port a multifactorial threshold model of inheritance in
which small genetic risk factors may interact with envir-
onmental factors.
Epigenetic changes, in particular DNA methylation,
can mediate both genetic and environmental factors and
may advance the understanding of the molecular patho-
genesis of orofacial clefts [14]. Several recent large stud-
ies [15–18] show that maternal exposure to putative
cleft risk factors, such as tobacco smoking, obesity, and
folate deficiency, can affect methylation profiles of blood
DNA in newborns and infants. Alvizi et al. [19] per-
formed an epigenome-wide association study of blood
DNA from 67 cases and 59 controls using Illumina
450K array and reported 578 differentially methylation
CpGs. In a Mendelian randomization analysis in the
Avon Longitudinal Study of Parents and Children
(ALSPAC) [20], Howe et al. [21] reported 21 putative
CpG sites where methylation might mediate genetic al-
lelic effects on liability to non-syndromic cleft lip/palate.
Sharp et al. [22] compared DNA methylation profiles be-
tween cleft subtypes (50 samples of each subtype) and
reported a total of 121 differentially methylated regions
(DMRs) in pairwise comparisons using blood DNA and
15 DMRs using lip/palate DNA. Here, we report a larger
epigenome-wide blood DNA methylation study from a




This study used blood samples from infants in our na-
tionwide population-based Norway Facial Cleft Study
(NCL), which has been previously described in detail [9].
Four hundred eighteen infants born with an orofacial
cleft during the years 1996 to 2001 were included: 107
CLO, 167 CLP, and 144 CPO. A total of 480 control in-
fants born without clefts were randomly selected from
all live births in Norway during that time period.
Heel-stick blood samples had been collected from all ba-
bies 2–3 days after delivery for phenylketonuria (PKU)
testing. These samples were stored and later used for
DNA methylation analysis. Demographic characteristics,
mother’s environmental exposures, and nutrition intake
were collected through questionnaires approximately 3
months after delivery.
Ethical approval for this study was obtained from the
Norwegian Data Inspectorate, the Regional Research
Ethics Committee for Western Norway, and the Institu-
tional Review Board of the US National Institute of En-
vironmental Health Sciences, National Institutes of
Health. Parents gave consent to data and sample collec-
tion, and all data were anonymized after collection.
DNA methylation measures
Genomic DNA was extracted from whole blood using
automated equipment (Autopure LS; Gentra, Minneap-
olis, MN). Extracted DNA was quantified using
Quant-iT™ PicoGreen dsDNA reagents (Invitrogen) and
stored at − 20 °C. One microgram of DNA was bisulfite
converted using the EZ-DNA Methylation kit (Zymo Re-
search, Irvine, CA) following the manufacturer’s proto-
col. Samples were randomly distributed across ten
96-well plates used for laboratory processing. The Illu-
mina HumanMethylation450 BeadChip (San Diego, CA)
was used to assess DNA methylation at 485,577 CpG sites
with 99% coverage of RefSeq genes and an average of 17
CpG sites per gene distributed across the promoter, 5′ un-
translated region (UTR), first exon, gene body, and 3′
UTR. At each CpG site on the array, the methylation level
was estimated using intensity measures of probes corre-
sponding to an unmethylated (U) or methylated (M) sig-
nal. Raw probe intensity values were extracted using R
package illuminaio (version 0.18.0) [23].
Methylation data pre-processing
Methylation raw IDAT files were preprocessed using
ENmix R package [24]. Briefly, we performed background
correction using the ENmix method [24]; fluorescent dye
bias between Cy3 and Cy5 was adjusted with the RELIC
method [25]; inter-array quantile normalization was applied
on methylation intensity values to make them comparable
between samples; and Infinium I and II probe-type design
Xu et al. Clinical Epigenetics           (2019) 11:40 Page 2 of 8
bias was adjusted using the RCP method [26]. The methyla-
tion level (β value) for each CpG site was calculated as the
ratio of normalized fluorescent intensities between methyl-
ated and unmethylated alleles β =M/(M+U+ 100).
We excluded 29 samples with low-quality methylation
data according to the following criteria: (1) average inten-
sity value across Illumina’s bisulfite internal control probes
less than 5500, (2) more than 5% of CpG probes having
low-quality data (Illumina detection P value > 10−6, read
from less than 3 beads, or outlier value for the probe in
the dataset), and (3) clear outliers based on visual inspec-
tion of a density plot of total intensity (U +M). We ex-
cluded one sample due to sex ambiguity. We also
removed poorly performing CpG probes as follows: (1)
CpGs (n = 23,264) with more than 5% low-quality data; (2)
CpGs (n = 53,247) with common SNPs (minor allele fre-
quency ≥ 0.05 in Europeans based on 1000 Genomes Pro-
ject data) located at the probe’s target CpG site, or probes
mapping to multiple genomic locations [27], or CpGs on
X or Y chromosomes; (3) we further excluded 1488 CpGs
with multiple mode distributions identified with ENmix R
package. After sample and CpG probe exclusions, 407,513
CpGs and 868 samples (456 controls, 105 CLO, 167 CLP,
and 140 CPO) remained for analysis.
Statistical analysis
An unconditional logistic regression model was
employed to perform epigenome-wide association ana-
lysis (EWAS). We tested for an association between
DNA methylation M values (logit transformation of β
values) at each CpG and a binary variable for each type
of orofacial cleft (shared controls vs. each cleft type:
CLO, CPO, CLP) or between cleft types (CLO vs CPO,
CLP vs CLO, and CLP vs CPO). In all association tests,
we adjusted for covariables including five surrogate vari-
ables (that explain 96% of variations in non-negative
control-probe data), plate, gender, calendar year of baby’s
birth, gestational age, and blood cell subtype compos-
ition. The proportions of five leukocyte subtypes (T cell,
B cell, granulocyte, monocyte, and natural killer cell)
were estimated using a method proposed by Houseman
et al. [28] with reference dataset GSE35069 [29]. To cor-
rect for multiple testing, we employed the Bonferroni
method and use P value threshold of 10−7 as the statis-
tical significance cutoff in all genome-wide analyses. All
statistical association analyses were performed using
the R software package (version 3.4). In addition to
the EWAS for individual CpG, we also used software
DMRcate [30] and Comb-P [31] to detect differen-
tially methylated regions (DMRs) based on individual
CpG P values from the EWAS. A DMR was defined as
regions containing at least two CpGs less than 1000
base pairs apart with Sidak multiple testing-corrected
P value < 0.05.
Results
Sample characteristics
To focus our investigation on non-syndromic facial clefts,
we excluded babies with other birth defects, resulting in
308 cases (92 CLO, 84 CPO, 132 CLP) and 436 controls
in the analysis. Demographic characteristics of these in-
fants and their mothers, as well as maternal exposures
during pregnancy, are summarized in Table 1. Compared
to controls, CLP cases are more likely to be male, and
CPO cases are more likely to be female. These are consist-
ent with the literature [32]. On average, infants with CLO
or CPO weigh slightly less at birth (ANOVA test P = 1.7 ×
10−2). Active maternal smoking during the first trimester
(≥ 1 cigarette per day) is positively associated with CLO
(OR = 2.5, CI = (1.6–4.0)) and CLP (OR = 1.8, CI = (1.2–
2.7)), but not with CPO (OR = 1.4, CI = (0.8, 2.3)), consist-
ent with an earlier analysis of the full dataset [7]. Mothers
with less education have an elevated risk of babies with
CLO (OR = 2.4, CI = (1.3–4.3)) and CLP (OR = 1.9, CI
= (1.1–3.3)). Lower dietary folate during pregnancy is a
risk factor for CPO (OR = 0.58, CI = (0.35–0.96)) [9]. Add-
itional maternal characteristics were examined, such as
age at delivery, body mass index (BMI), and multivitamin
use, but none were associated with facial clefts.
Orofacial cleft-associated CpG sites
We used unconditional logistic regression models to test
whether the DNA methylation profile in blood of 2–3-day--
old infants was associated with cleft phenotype at each
CpG site on the array. Considering potential etiologic dif-
ferences between cleft types, we first examined the associ-
ation for CLO, CPO, and CLP separately, using as a
reference the same group of unaffected control babies.
After Bonferroni correction for multiple testing, there were
no statistically significant associations for any of the ana-
lyses (Additional file 1: Figure S1), perhaps reflecting the
small sample size in each case group. Consistent with other
epidemiological studies, we then combined CLO and CLP
case group as the “any cleft lip” group and repeated the as-
sociation analysis (Additional file 1: Figure S2). This analysis
identified one significant probe (cg09696939, P = 9.58 ×
10−8) at gene BICC1 (Table 2). We also combined CPO
with the CLP group as the “any cleft palate” group
(Additional file 1: Figure S2) and identified another signifi-
cant probe (cg26985354, P = 7.38 × 10−8) in CLASRP gene
(Table 2). Additional file 2: Table S1 lists 43 CpG probes
with P value less than 10−5 in any of the comparisons. Simi-
lar to Alvizi et al. [19], we compared controls with “any
cleft” group (combining all three case groups together), but
did not find any significant dmCpG at genome-wide signifi-
cance level of 10−7. Similar to Sharp et al. [22], we also
compared methylation profiles between cleft types (CLO vs
CLP, CPO vs CLP, CLO vs CPO), but again did not identify
any significant CpGs with P value < 10−7.
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Table 1 Characteristics of infants and mothers
Control CLO CPO CLP
Infants 436 92 84 132
Sex, n (%)
Female 198 (45) 41 (45) 47 (56) 37 (28)
Male 238 (55) 51 (55) 37 (44) 95 (72)
Birth weight, kg 3.6 ± 0.6 3.4 ± 0.7 3.5 ± 0.6 3.6 ± 0.6
Gestational age, days 277.7 ± 11.6 274.8 ± 14.6 276.4 ± 13.8 278.6 ± 11.7
Mothers
Age at delivery, years 29.1 ± 4.8 28.9 ± 4.6 29.2 ± 5.0 29.4 ± 5.4
Active smokera, n (%)
No 316 (72) 47 (51) 55 (65) 78 (59)
Yes 120 (28) 45 (49) 29 (35) 54 (41)
Alcohol useb, n (%)
0 292 (66) 52 (56) 56 (66) 80 (61)
1–3 73 (17) 19 (21) 14 (17) 28 (21)
4–6 26 (6) 6 (7) 8 (10) 8 (6)
≥ 7 42 (10) 12 (13) 6 (7) 14 (11)
Missing 3 (1) 3 (3) 0 (0) 2 (1)
BMI (kg/m2) 23.5 ± 3.9 23.5 ± 3.7 23.7 ± 4.8 23.3 ± 4.1
Folic acid supplement, μgc,d, n (%)
0 261 (60) 59 (65) 47 (56) 94 (71)
1–399 90 (21) 17 (18) 19 (23) 24 (18)
≥ 400 85 (19) 16 (17) 18 (21) 14 (11)
Dietary folate, μg, n (%)
0–171 110 (25) 28 (31) 31 (37) 41 (31)
172–214 96 (22) 21 (23) 21 (25) 36 (27)
215–264 112 (26) 16 (17) 9 (11) 21 (16)
≥ 265 96 (22) 16 (17) 20 (24) 25 (19)
Missing 22 (5) 11 (12) 3 (3) 9 (7)
Multivitaminsd, n (%)
No 277 (64) 65 (71) 50 (60) 96 (73)
Yes 159 (36) 27 (29) 34 (40) 36 (27)
Education, n (%)
Less than high school 45 (10) 20 (22) 9 (11) 24 (18)
High school and above 391 (90) 72 (78) 75 (89) 108 (82)
aDuring the first trimester
bTotal number of drinks during the first trimester
cAny intake of folic acid supplements (either alone or with multivitamins)
dDuring month prior to pregnancy and first 2 months of pregnancy
Table 2 CpGs associated with non-syndromic clefts
CpG Chr Position Gene Methylation Coef. P Phenotype
cg09696939 10 60,272,079 BICC1 0.019 2.304 9.6 × 10−8 Any cleft lip
cg26985354 19 45,567,180 CLASRP 0.889 − 1.45 7.4 × 10−8 Any cleft palate
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Epidemiological studies have suggested that multiple
environmental exposures may affect the incidence of
clefts. As a sensitivity analysis, we repeated the above as-
sociation analyses while further adjusting for smoking,
BMI, alcohol intake, folate intake, and gestational age. A
total of 45 CpGs have association P values less than
10−5, and 30 of them overlap with the 43 CpGs from un-
adjusted analyses (Additional file 2: Table S2).
Using a Mendelian randomization analysis method
with SNP and DNA methylation data in cord blood
samples from the general population ALSPAC cohort,
Howe et al. [21] identified 21 CpGs related to clefts.
Four of the 21 CpGs did not pass quality control in
our dataset. Additional file 2: Table S3 lists average
methylation levels for the remaining 17 CpGs and re-
lated case-control association analysis results. We
found statistically significant association for three of
the CpGs at an unadjusted P value threshold of 0.05, in-
cluding two (cg11398452 and cg02598441) of the five
CpGs that passed a reverse-causation test reported by
Howe et al. [21]. However, the direction of effect for two
of the CpGs (cg02598441 and cg23166289) was reversed
compared to Howe’s results. Although Howe’s and our
NCL study show concordant direction of effect for CpG
cg11398452, a Brazilian EWAS conducted by Alvizi et al.
EWAS [19] reported an opposite direction of effect for
this CpG. The Brazilian EWAS reported that 578 CpGs
were differentially methylated between 59 controls and 67
combined cleft cases. Although 37 of these CpGs have un-
adjusted P value < 0.05 in our comparison of controls to
combined cases, 33 (89%) have the opposite direction of
effect (Additional file 2: Table S4).
Based on the GWAS Catalog (https://www.ebi.ac.uk/
gwas/) and literature review of genetic linkage and asso-
ciation studies, we found 137 genes previously reported
to be related to syndromic or non-syndromic clefts. Of
the 3506 CpG probes on the Illumina 450K array located
within 5 kb of these genes, 196 CpGs in 82 of these genes
have association P value less than 0.01 (Additional file 2:
Table S5). However, the proportion of small P value CpGs
is not greater than array averages (binomial test P = 0.13),
and no CpG in these genes had an association P value less
than 10−5.
Differentially methylated region analysis
We used two different methods to search for DMRs.
Searches using DMRcate [30] software (with bandwidth
at the default setting of 1000 nucleotides) found no sig-
nificant DMRs. However, searches using Comb-P soft-
ware identified a number of DMRs. In the comparisons
of controls to individual cleft subtypes, we identified 10
DMRs for CLO, 6 for CPO, and 41 for CLP (Table 3,
Additional file 2: Table S6). DMR (Chr6:28,583,971–
28,584,289), comprising 14 CpGs in an intergenic region
(between gene SCAND3 and LOC401242), was found in
all three comparisons. Comparisons of controls to com-
bined case subtypes identified 26 DMRs for CLP+CLO,
31 for CLP+CPO, and 37 DMRs when all case subtypes
were combined. Some DMRs are found in multiple
comparisons (Table 3, Additional file 2: Table S6).
Similar to Sharp et al. [22], we also conducted DMR
analysis between case subtypes and identified 10
DMRs in CLO compared to CPO, 9 DMRs in CLP
compared to CLO, and 13 DMRs in CLP compared to
CPO (Additional file 2: Table S6). DMR (17:80,541,737–
80,542,007 in gene FOXK2) was identified in three com-
parisons (CLP vs CPO, CLO vs CPO, and control vs CPO)
(Additional file 2: Table S6) and is also reported by Sharp’s
study in one comparison (CLO vs CPO). EWAS results
for individual CpGs within significant DMRs are listed in
Additional file 2: Table S7.
Epigenetic age and orofacial cleft
Biological age estimated using DNA methylation data
(epigenetic age) was recently reported to be associated
with all-cause mortality [33]. Age acceleration (difference
Table 3 Number of significant DMRs and overlaps between them. The number of overlapped CpGs within each DMR is shown in
parenthesis
EWAS Case-control comparison Case-case comparison
CLO CPO CLP CLP+CLO CLP+CPO All case CLO vs CPO CLP vs CLO CLP vs CPO
CLO 10 (75) 1 (14) 1 (14) 4 (28) 1 (14) 3 (22) 0 (0) 2 (21) 0 (0)
CPO 6 (33) 1 (14) 1 (14) 3 (19) 3 (19) 2 (7) 0 (0) 1 (2)
CLP 41 (275) 8 (67) 9 (73) 9 (76) 0 (0) 2 (10) 0 (0)
CLP+CLO 26 (184) 9 (83) 19 (134) 0 (0) 0 (0) 1 (4)
CLP+CPO 31 (198) 17 (118) 0 (0) 2 (10) 0 (0)
All case 37 (222) 0 (0) 0 (0) 0 (0)
CLO vs CPO 10 (45) 0 (0) 4 (21)
CLP vs CLO 9 (108) 0 (0)
CLP vs CPO 13 (64)
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between epigenetic age and chronological age) could be
used to indicate development rate in newborns. The
blood samples in our study were collected from all ba-
bies 2–3 days after delivery, and thus, the chronological
age is essentially 0 year old. We found that methylation
age estimated using the Horvath method [34] was in
general younger (~ 0.4 years) than the chronological age
for our study participants. The means and standard de-
viations of epigenetic ages are − 0.39 ± 0.10, − 0.40 ±
0.11, − 0.41 ± 0.09, and − 0.40 ± 0.10, respectively, for
controls, CLO, CPO, and CLP. Epigenetic age estimates
for any of the cleft groups are slightly younger than
those of the controls, but none of the pairwise compari-
sons are statistically significant (Tukey honest signifi-
cant differences test, P > 0.1).
Discussion
We conducted an epigenome-wide association study in-
vestigating 2–3-day-old infant blood DNA methylation
and isolated orofacial clefts. We did not find individual
dmCpG when we analyzed each cleft type separately.
When we combined the cleft palate only with the cleft
lip and palate, we identified one significantly methylated
probe cg09696939 near gene BICC1. Similarly, when we
combined the cleft lip only with the cleft lip and palate,
we identified another significant dmCpG cg26985354 in
gene CLASRP. Based on EWAS P values for individual
CpGs and their chromosome location, we identified
multiple differentially methylated regions (DMRs) be-
tween controls and case subtypes, and in case-case ana-
lysis of different subtypes. We confirmed one of the
DMRs (17:80,541,737–80,542,007 in gene FOXK2) previ-
ously reported in case-case analysis by Sharp et al. [22].
CpG cg09696939 is located on chromosome 10, 824
base pairs upstream of gene BICC1. It is located in a CpG
shore region and hypomethylated (averaged methylation
level is 0.02). BICC1 encodes an RNA-binding protein,
acts as a negative regulator of Wnt signaling, and is active
in regulating gene expression by modulating protein
translation during embryonic development. The gene is
reported to be associated with cystic and renal dysplasia
[35], myopia [36], and Alzheimer disease [37].
CpG cg26985354 is located on chromosome 19, in an
intron of the gene CLASRP (CLK4-associating serine/
arginine-rich protein). It is in a CpG island region and is
hypermethylated (averaged methylation level is 0.89).
CLASRP is a protein-coding gene, which functions as an
alternative splicing regulator and may regulate members
of the CLK kinase family [38].
Although we did not find any differentially methylated
genomic regions using the DMRcate method [30], we
found multiple DMRs using the Comp-P method [30],
perhaps reflecting increased sensitivity of Comp-P when
effect sizes are small. Compared to controls, CLP had
the most DMRs (41 DMRs), followed by CLO (10
DMRs) and CPO (6 DMRs); only one DMR, in an intra-
genic region on chromosome 6, was shared among the
three case subtypes. The number of DMRs found in
each subtype could reflect sample size and resulting
power (n = 132 CLP samples, 92 CLO samples, and 84
CPO samples). Subtype-specific DMRs might arise be-
cause of etiologic heterogeneity [22], but we cannot dis-
miss the possibility that they arise by chance.
In a study of a general population cohort without clefts,
Howe et al. [21] found that cleft-associated polymorphisms
predicted differential methylation of 21 CpGs. Although
we found weak statistical support for three of these CpGs
(threshold P < 0.05), the directions of effect for two were
opposite from Howe’s prediction [21] and the third had an
opposite direction of effect in an independent EWAS ana-
lysis of clefts [19, 21]. A study of blood DNA from
5-year-old children by Alvizi et al. [19] compared 67 com-
bined cleft cases to 59 controls and reported 578 dmCpGs.
But in our study, only 3 of these had the same direction of
effect and met a threshold of unadjusted P < 0.05—fewer
than expected by chance. A case-only study by Sharp et al.
[22] of both blood and cleft tissue (with 50 samples of each
cleft subtype) reported 335 dmCpGs when comparing
CLO to CPO. However, we did not find any significant
CpGs when performing similar case-case analysis in our
NCL dataset. Sharp et al. also reported 121 DMRs, and we
confirm one of the DMRs they report in the gene FOXK2.
But while they found this DMR in a comparison of CLO vs
CPO, we found it in CLO vs CPO, CLP vs CPO, and con-
trol vs CPO. Similar to Sharp et al., we also found that
methylation age estimates for CLP were slightly higher
than those for CLO and CPO although in our analysis
none of these differences were statistically significant. The
low replicate rate could be due to small sample size, age,
and study design differences.
Unlike genotype, which remains constant, epigenetic pro-
files may change over time and in response to exposure.
One of the most important strengths of our study is that
blood samples for cases and controls used in analysis were
uniformly collected and stored soon after delivery as part of
a standardized PKU screening program across all regions of
Norway, thus minimizing case-control differences in age,
collection, handling, and storage. The study includes nation-
wide enrollment of all newborns referred for cleft surgery in
Norway, with controls selected by random sampling from
among all live births in Norway during the same period.
Our study also has limitations. Although larger than prior
cleft-methylation studies, our sample size is still relatively
small, particularly when considering specific cleft subtypes.
Orofacial clefts result from fusion failures in very early
pregnancy. We compared DNA methylation profiles be-
tween cleft cases and controls from blood samples at birth,
and those results may not be an accurate surrogate for
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methylation differences in the relevant target tissues during
early fetal life. Methylation differences in the blood of new-
borns could be caused by cleft-related differences in genetic
or environmental exposures, but could also be the conse-
quence of other unmeasured factors or due to chance.
Conclusions
Using newborn blood DNA, we identified two CpGs and
multiple genomic regions that are differentially methyl-
ated between controls and cleft cases, and additional dif-
ferences between cleft subtypes. These findings lend
some support to the hypothesis that aberrant DNA
methylation profiles may be related to orofacial clefts.
Additional files
Additional file 1: Figure S1. EWAS test results for comparisons
between shared controls and cleft subtypes (CLO, CPO and CLP). Shown
are the -log10(P) multiplied by sign of methylation coefficient estimated
using unconditional logistic regression. Figure S2. EWAS test results for
comparisons between shared controls and combined cleft subtypes (CLP
+CPO and CLP+CLO). Shown are the -log10(P) multiplied by sign of
methylation coefficient estimated using unconditional logistic regression.
(DOCX 463 kb)
Additional file 2 Table S1. CpG probes with association P value less
than 10−5 in any one of the cleft subtype analysis. Unconditional logistic
regression model was used to test for association between DNA
methylation M value and cleft status (shared controls vs. each cleft type).
Covariables adjusted in each test are control surrogate variables, plate,
gender, calendar year of baby’s birth, gestational age, and blood cell
subtype composition. Table S2. Sensitivity analysis results by further
adjusting for mother’s smoking status, BMI, drinking, folate intake and
gestational age. Shown are CpG probes with association P value less than
10−5 in any one of the cleft subtype analysis. Unconditional logistic
regression model was used to test for association between DNA
methylation M value and cleft status (shared controls vs. each cleft type).
Total covariables adjusted in each test are control surrogate variables,
plate, gender, calendar year of baby’s birth, gestational age, blood cell
subtype composition, smoking, BMI, drinking, folate intake and
gestational age. Table S3. CpGs reported to be associated with cleft
using Mendelian randomization analysis by Howe et al. 2018. Shown are
the analysis results in NCL dataset: mean methylation level in control
groups, all cleft case combined group(case), and case subgroups; case-
control logistic regression estimated coefficient and P values for the
combined case group and case subgroups. Table S4. Methylation means
and association P values (controls compared to combined cleft cases) in
Alvizi et al. (Scientific Reports, 2016) study and NCL study. Shown are the
overlapped CpGs between NCL study and 578 CpGs reported by Alvizi et
al. Table S5. Candidate gene results. Shown are CpGs around literature
reported cleft-associated genes with methylation association P value less
than 0.01 in any one of the cleft subtype analysis. Table S6. Differentially
methylated regions (DMR) with Sidak multiple testing corrected P value
< 0.05. Table S7. CpGs and association results within differentially
methylated regions. (ZIP 229 kb)
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